Lynx Financial

Bone Index Finland Ltd. is a company specializing in osteoporosis diagnostics, founded in 2011 and headquartered in Kuopio, Finland. The company's primary product, Bindex, is a device designed to measure multisite cortical bone thickness, which aids in diagnosing osteoporosis in accordance with international guidelines. Unlike traditional DXA devices typically found in hospitals, Bindex offers a quick and simple method for assessing bone health by measuring the cortical thickness of the tibia. This information, when combined with other patient data, allows for the estimation of bone mineral density in the hip region. Bindex's efficiency makes it suitable for large-scale screenings of high-risk groups, enabling earlier identification of osteoporosis risk before fractures occur. This proactive approach not only enhances patient quality of life but also contributes to reducing public healthcare costs.

Elucida Oncology develops a nanoparticle drug delivery platform for cancer detection, real-time visualization, and treatment. Its core technology, the Target/Clear C-Dot platform, encapsulates near-infrared dye within rigid silica shells that target cancer cells and clear out via the renal system. The platform is used across diagnostic imaging, surgical applications, and various therapeutic treatments for primary solid tumors and metastatic cancers.

Aurealis Therapeutics focuses on developing curative treatments for non-healing wounds and complex inflammatory diseases. Their flagship product, AUP-16, is a four-in-one biologic drug designed to accelerate healing and modulate the immune system.

Novuson, Inc. is a medical device company based in Bothell, Washington, founded in 2014 as a spinout from the University of Washington's Applied Physics Laboratory. The company specializes in manufacturing ultrasonic surgical devices that utilize Direct Therapeutic Ultrasound (DTU) technology to offer coagulation and hemostatic control during surgical and trauma procedures. Novuson's platform includes various components, such as an ultrasonic clamp, a beam ablation/cauterization probe, and a precision beam ultrasonic scalpel. These devices enable clinicians to treat or remove tumors and manage bleeding in solid organs and highly vascularized tissues without complications. By delivering focused ultrasound energy, Novuson's products aim to enhance surgical efficiency, reduce operational costs, and improve patient outcomes through swift and robust hemostasis, cauterization, and tissue division.